Clinical Pipeline

DiscoveryPhase 1Phase 2Phase 3Marketed

Multiple Targets and Therapeutic Areas


Partner: gsk-med

Collaborative program:  Astex Pharmaceuticals and GlaxoSmithKline entered into a collaboration agreement to discover, develop and commercialize novel compounds directed against multiple therapeutic targets of interest to GSK in November 2009.

Under the collaboration, Astex applied its fragment chemistry platform, Pyramid™, to multiple targets identified by GSK, with the objective of identifying and developing new candidate drugs. The targets were selected from multiple therapeutic areas within GSK. GSK are progressing potential drug candidates derived from the collaboration; the most advanced has entered a Phase 1 clinical trial.